Q3 2024

Filed Nov 12, 2024 · 10-Q · 43 days after period end · 0000950170-24-125399

Q3 2024 · 10-Q

Revenue—

Net Income

-$15.12M

N/M vs Q3 2023

EPS Diluted

-$0.21

N/M vs Q3 2023

Operating Income-$18,634,000N/M

Operating Cash Flowderived$3,366,000N/M

Same quarter

Metric	Q3 2024	Q3 2023	Q3 2022	Q3 2019
Revenue	—	$2.19M	$1.72M	$1.92M
Net Income	-$15.12M	-$10.36M	-$4.07M	-$1.13M
EPS Diluted	-$0.21	-$0.37	—	-$0.02

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR